Product Name:    JZL 195

Synonyms:    JZL 195;4-nitrophenyl 4-(3-phenoxybenzyl)piperazine-1-carboxylate;4-[(3-Phenoxyphenyl)methyl]-1-piperazinecarboxylic acid 4-nitrophenyl ester;CS-1586;JZL-195;JZL 195;JZL195;1-Piperazinecarboxylic acid, 4-[(3-phenoxyphenyl)methyl]-, 4-nitrophenyl ester;4-Nitrophenyl 4-[(3-phenoxyphenyl)methyl]-1-piperazinecarboxylate;Autophagy,Monoacylglycerol lipase,inhibit,MAGL,Fatty acid amide hydrolase,JZL-195,JZL195,Inhibitor,FAAH,JZL 195

CAS:    1210004-12-8

MF:    C24H23N3O5

MW:    433.46

Fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) mediate the hydrolysis of the endocannabinoids arachidonoyl ethanolamide (AEA) and 2-arachidonoylglycerol (2-AG), respectively. JZL 195 is a potent inhibitor of both FAAH and MAGL (IC50s = 2 and 4 nM, respectively). It poorly inhibits neuropathy target esterase and ABHD6 and does not inhibit other brain serine hydrolases. JZL 195 displays time-dependent inhibition of FAAH and MAGL in vivo, consistent with a covalent mechanism of activation. The in vivo inhibitory actions of JZL 195 against FAAH and MAGL are comparable to those of the selective inhibitors PF-3845 and JZL 184 , respectively. Through its inhibitory actions, JZL 195 simultaneously augments brain levels of AEA and 2-AG, producing antinociceptive, cataleptic, and hypomotility effects like those produced by direct CB1 agonists.